Johnson & Johnson Seeks to End Decade-Long Talc Litigation

The giant pharmaceutical company, Johnson & Johnson (J&J), has offered a $5.5 billion settlement offer to end the litigation involving lawsuits brought against it because its products made from talc, especially its popular baby powder, cause ovarian cancer. This deal is intended to help end a legal battle that has been ongoing for over a decade, among the most costly and longest ones in the history of J&J. The deal will be successful only if at least 95 percent of claimants agree to it.

Settlement Follows Earlier Legal Setbacks and Court Victories

The latest offer is coming following the failure of J&J to resolve the lawsuits using the bankruptcy approach. In 2019, a bankruptcy judge turned down a $9 billion offer made by the company's subsidiary called Red River Talc. Instead of appealing the ruling, the company decided to proceed with defending itself against the lawsuits.

J&J has lately enjoyed favorable court rulings. One of the federal judges wondered whether plaintiffs could provide scientific proof that linked the talc products to ovarian cancer. This judge challenged the plaintiffs to justify the continued processing of thousands of cases where there was no proof linking the product and the illness.

Payment Plan and Company Position

As per the settlement, J&J intends to make an upfront payment of up to $3 billion in the coming year, followed by other payments beginning in 2028. According to the firm, the settlement will enable it to put an end to the litigation and focus further on healthcare innovations.

According to Erik Haas, worldwide vice president of litigation at the firm, J&J is still convinced that it would have won the case, but the settlement represents a realistic way forward for all the parties. J&J insists that its talcum powder products are safe and there is no scientific evidence linking them to the development of ovarian cancer.

Most Talc Claims Already Resolved

According to Johnson & Johnson, it has already settled 95 percent of its mesothelioma cases, as well as claims against it by states on consumer-protection grounds, and cases relating to talcum powder suppliers. This settlement is mainly aimed at the approximately 76,000 pending cases for ovarian cancer. It could cost more than $7 billion depending on participation.

Market Responds Positively

The stock markets responded favorably to the news, and the shares of Johnson & Johnson increased by over 2 percent prior to the opening of the market. Should a sufficient number of plaintiffs agree to the deal, the settlement will mark the conclusion of one of the biggest product liability lawsuits in the healthcare industry and enable the company to concentrate on its primary lines of business.